Evidence map›Paper›PMID 38896335›Full record

ArticleInternational journal of hematology2024

Detection of factor XIII inhibitors in 33 patients with autoimmune factor XIII deficiency in Japan.

Masayoshi Souri, Tsukasa Osaki, Akitada Ichinose

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Masayoshi SouriDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, 990-9585, Japan.
Tsukasa OsakiDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, 990-9585, Japan.
Akitada IchinoseDepartment of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, 990-9585, Japan. aichinos@med.id.yamagata-u.ac.jp.ORCID http://orcid.org/0000-0002-3807-5628

Funding

the Japan Agency for Medical Research and Development 16ek0109043h0003the Japan Agency for Medical Research and Development AMEDthe Japanese Ministry of Education, Culture, Sports, Science and Technology 16K09820the Japanese Ministry of Education, Culture, Sports, Science and Technology MEXTthe Japanese Ministry of Health, Labor, and Welfare 21FC1008the Japanese Ministry of Health, Labor, and Welfare MHLW
6 · The paper itself

Abstract

Autoimmune factor XIII (FXIII) deficiency (AiF13D) is a rare hemorrhagic disease. The anti-FXIII autoantibodies that cause this disease are classified into three types: type Aa inhibits the heterotetramer assembly and activation of FXIII, type Ab inhibits the enzymatic activity of activated FXIII, and type B enhances the elimination of FXIII from the blood. The former two are FXIII inhibitors and may be lethal if overlooked by conventional functional assays. To reliably detect both types of FXIII inhibitors, a new assay was developed by incorporating 5-(biotinamido)pentylamine (BAPA) into α

Indexed as

AutoantibodiesFactor XIIIFactor XIII DeficiencyAdultAgedAutoimmune DiseasesFemaleHumansJapanMaleMiddle AgedSensitivity and SpecificityAutoantibodiesFactor XIIIAcquired bleeding disorderAmine incorporation assayAnti-factor XIII autoantibodyFactor XIII inhibitorα2-plasmin inhibitor

Identifiers

PMID38896335

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.